Cancer Stem Cells: the elusive tumour population discussed
DOI:
https://doi.org/10.54097/m8qd7672Keywords:
Cancer; Stem cells; Cancer Stem Cells; tumour resistance; targeted therapies.Abstract
Cancer Stem Cells (CSCs) are specific tumour populations playing important roles in tumour initiation, progression, and resistance to conventional therapies. Their involvement in processes like epithelial-to-mesenchymal transition makes them crucial players in metastasis. Traditional therapies often fall short in targeting CSCs due to their quiescent nature during treatments and their adaptability, such as increased resistance post-radiotherapy. CSC antigen heterogeneity also poses challenges to targeted therapy. Examples of CSC-targeting approaches are CAR-T cells and oncolytic viruses, discussed in this paper. Stem cells, present promising avenues for CSC-targeted therapies due to their potential as immune progenitor cells and inherent attraction to CSCs. This review provides an overview of the roles of CSCs in cancer, some examples CSC-targeted cell therapies, the potential of stem cells in these therapies, and the challenges and future directions in this critical area of cancer research.
Downloads
References
Capp JP. Cancer Stem Cells: From Historical Roots to a New Perspective. J Oncol. 2019;2019:1-10.
Yang L, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020; 5(1):8.
Kuşoğlu A, et al. Cancer stem cells: A brief review of the current status. Gene. 2019;681:80-85.
Clarke MF, et al. Cancer Stem Cells—Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells. Cancer Res. 2006;66(19):9339-9344.
Liu H, et al. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling. Breast Cancer Res. 2023;25(1):43.
Chu DT, et al. Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications. Cells. 2020;9(3):563.
Zhang CL, et al. Stem cells in cancer therapy: opportunities and challenges. Oncotarget. 2017;8(43):75756-75766.
Efremov YR, et al. Cancer Stem Cells: Emergent Nature of Tumor Emergency. Front Genet. 2018;9:544.
Walcher L, et al. Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Front Immunol. 2020;11:1280.
Al-Hajj M, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983-3988.
Kreso A, Dick JE. Evolution of the Cancer Stem Cell Model. Cell Stem Cell. 2014;14(3):275-291.
Gupta PB, et al. Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells. Cell. 2011;146(4):633-644.
Wu M, et al. Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosis. Nat Commun. 2022;13(1):1371.
Campbell LL, Polyak K. Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution? Cell Cycle. 2007;6(19):2332-2338.
Fulawka L, et al. Cancer stem cells - the current status of an old concept: literature review and clinical approaches. Biol Res. 2014; 47(1):66-66.
Nieto MA, et al. EMT: 2016. Cell. 2016;166(1):21-45.
Lo Iacono M, et al. Destroying the Shield of Cancer Stem Cells: Natural Compounds as Promising Players in Cancer Therapy. J Clin Med. 2022;11(23):6996.
Masoumi J, et al. Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects. Acta Pharm Sin B. 2021;11(7):1721-1739.
Rezayatmand H, et al. Drug resistance in cancer therapy: the Pandora’s Box of cancer stem cells. Stem Cell Res Ther. 2022;13(1):181.
Takeishi S, Nakayama KI. To wake up cancer stem cells, or to let them sleep, that is the question. Cancer Sci. 2016;107(7):875-881.
Espinosa-Sánchez A, et al. Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness. Front Oncol. 2020; 10:1533.
Krause M, et al. Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Adv Drug Deliv Rev. 2017;109:63-73.
Li F, et al. Radiation induces the generation of cancer stem cells: A novel mechanism for cancer radioresistance. Oncol Lett. 2016;12(5):3059-3065.
Chi HC, et al. Roles of Long Noncoding RNAs in Recurrence and Metastasis of Radiotherapy-Resistant Cancer Stem Cells. Int J Mol Sci. 2017;18(9):1903.
Watanabe Y, et al. Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours. Br J Cancer. 2023;128(5):886-895.
Cui X, et al. CAR-T therapy: Prospects in targeting cancer stem cells. J Cell Mol Med. 2021;25(21):9891-9904.
Tousley AM, et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature. 2023;615(7952):507-516.
Manni S, et al. Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies. Nat Commun. 2023;14(1):3423.
Santos Apolonio J, et al. Oncolytic virus therapy in cancer: A current review. World J Virol. 2021;10(5):229-255.
Shalhout SZ, et al. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20(3):160-177.
Gillespie GY, et al. Oncolytic viral therapy: targeting cancer stem cells. Oncolytic Virotherapy. Published online February 2014:21.
Kamta J, et al. Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches. Front Oncol. 2017;7.
Fukuhara H, et al. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci. 2016;107(10):1373-1379.
Ueda T, et al. Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. Nat Biomed Eng. 2023;7(1):24-37.
El-Kadiry AEH, et al. Cell Therapy: Types, Regulation, and Clinical Benefits. Front Med. 2021;8:756029.
Santamaria S, et al. Will a mAb-Based Immunotherapy Directed against Cancer Stem Cells Be Feasible? Front Immunol. 2017;8:1509.
Bar-Hai N, Ishay-Ronen D. Engaging plasticity: Differentiation therapy in solid tumors. Front Pharmacol. 2022;13. Accessed July 12, 2023. https://www.frontiersin.org/articles/10.3389/fphar.2022.944773
De Thé H. Differentiation therapy revisited. Nat Rev Cancer. 2018;18(2):117-127.
Enane FO, et al. Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis. 2018;9(9):1-15.
Nayak A, et al. Cancer Stem Cells and the Tumor Microenvironment: Targeting the Critical Crosstalk through Nanocarrier Systems. Stem Cell Rev Rep. 2022;18(7):2209-2233.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
